Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease
In a Research Article exclusively free for members, Andrea F Wise et al. from Monash University (Australia) investigate investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease, and therefore have potential for therapeutic intervention.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet – the regenerative medicine network
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.